中国经济网北京8月21日讯(记者 郭文培)8月21日，金城医药发布2025年半年度报告。报告期内，公 司实现营收13.60亿元，同比下降22.65%；实现归属于上市公司股东的净利润0.43亿元，同比下降 66.78%。 从具体业务板块收入看，报告期内，除生物制药及特色原料药系列产品营收实现正增长外，金城医 药头孢侧链活性酯系列产品、制剂产品、其他医药化工产品的营收较上年同期均有回落。同时，上述四 大板块产品的毛利率上半年均降低。 | | 营业收入 | 营业成本 | 毛利率 | 营业收入比上 年同期增减 | 营业成本比上 年同期増減 | 毛利率比上年 同期增减 | | --- | --- | --- | --- | --- | --- | --- | | 分产品或服务 | | | | | | | | 头孢侧链活性酯 系列产品 | 297,598,253.09 | 208,729, 497. 07 | 29. 86% | -32. 20% | -27.73% | -4. 35% | | 生物制药及特色 原料药系列产品 | 230, 198, 218. 45 | 124, 336, 244, 48 | 45. 99 ...

Core Viewpoint - The company has established a comprehensive development layout supported by five strategic areas, focusing on pharmaceuticals, synthetic biology, women's health technology, high-end anti-infection, and new tobacco fields [2]. Company Overview - The company specializes in the pharmaceutical and chemical industry, with key products including a series of cephalosporin side-chain active esters, biopharmaceuticals, specialty raw materials, and various formulations [2]. - Major products include AE active esters, cephalosporin derivatives, glutathione, and various dosage forms such as oral, topical, and injectable products targeting anti-infection and women's health [2]. Financial Data and Indicators - The company does not require retrospective adjustments or restatements of previous annual accounting data [3]. - There are no significant discrepancies between the financial indicators disclosed in quarterly and semi-annual reports [4].